This first-edition “2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases”estimates the prevalence of nonexudative retinal diseases and forecasts the treatment market by region for complement inhibitors, gene therapies, and more.
The report examines clinical-stage drug-development programs, reviews the development stages of drug- delivery platforms, and analyzes trends in doctor interest in complement inhibitors in both the United States and Western Europe, as well as patient dosing with complement inhibitors in the United States.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.